Vaxcell
Cell-based immunotherapeutics for advanced cancer treatment.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | Grant | |
| Total Funding | 000k | ||
| KRW | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | 13737 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | (70565 %) | (454 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | (74866 %) | (559 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | - | 35845 % | 318 % |
Source: Company filings or news article
Vaxcell-Bio Therapeutics is a South Korean biotechnology company engaged in the research and development of cell-based and protein-based immunotherapeutics for treating cancer. Founded in 2010 by Je-Jung Lee, a prominent hematologist in Korea, the company aims to provide innovative treatments for refractory cancers in both humans and animals. Vaxcell-Bio went public in 2020, listing on the KOSDAQ exchange.
The company's core business revolves around several technology platforms, including the Vax-NK platform for Natural Killer (NK) cells, the Vax-DC platform for dendritic cells, and next-generation CAR (Chimeric Antigen Receptor) platforms like CAR-T, CAR-NK, and CAR-MIL. Its lead candidate, Vax-NK/HCC (VCB-1102), is an NK cell therapy for advanced hepatocellular carcinoma (liver cancer) which has completed Phase 2a clinical trials, demonstrating a 100% disease control rate when used in combination with chemotherapy. Another key candidate is Vax-DC/MM, a dendritic cell therapy for multiple myeloma. The company has received therapeutic use approval in Korea for Vax-NK/HCC, allowing its use in patients with advanced liver cancer who have exhausted other options. Vaxcell-Bio is also developing therapies for small cell lung cancer and pancreatic cancer.
In addition to human therapies, Vaxcell-Bio has an Animal Immune Platform. Its product, Vaxleukin-15, is an approved immuno-oncology drug for treating canine mammary tumors and lymphoma in South Korea. The company generates revenue through direct sales, technology transfers, and contract development and manufacturing organization (CDMO) services, leveraging its advanced biopharmaceutical manufacturing license and GMP-certified facilities. Vaxcell-Bio actively pursues global patents to protect its technologies and has engaged in strategic mergers and partnerships, such as acquiring ALBIOTEK to integrate its bispecific antibody platform and drug delivery system technology.
Keywords: cancer immunotherapy, cell therapy, natural killer cells, NK cell, CAR-T, dendritic cells, oncology, liver cancer, hepatocellular carcinoma, multiple myeloma, pancreatic cancer, animal health, canine oncology, Vax-NK, Vax-DC, Vaxleukin-15, clinical trials, biopharmaceutical, regenerative medicine, CDMO, Je-Jung Lee, KOSDAQ